Literature DB >> 32458993

Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.

Cristiano Pagnini1, Maria Carla Di Paolo1, Giulia De Angelis1, Federica Torcolacci1, Michele Milano1, Daniela Trinca1, Roberto Porciello2, Maria Giovanna Graziani1.   

Abstract

Entities:  

Keywords:  BS2; CT-P13; Crohn’s disease; infliximab biosimilar; psoriasis

Year:  2020        PMID： 32458993     DOI： 10.1093/ibd/izaa128

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  2 in total

Review 1.  Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

Authors:  Eduardo Mysler; Valderilio Feijó Azevedo; Silvio Danese; Daniel Alvarez; Noriko Iikuni; Beverly Ingram; Markus Mueller; Laurent Peyrin-Biroulet
Journal:  Drugs       Date:  2021-10-27       Impact factor: 9.546

2.  Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.

Authors:  Hillel P Cohen; Sohaib Hachaichi; Wolfram Bodenmueller; Tore K Kvien; Silvio Danese; Andrew Blauvelt
Journal:  BioDrugs       Date:  2022-07-26       Impact factor: 7.744
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.